Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

Recruiting now · Phase 2

Conditions studied: Post-Dural Puncture Headache

In brief

The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.

Key facts

Study ID

NCT05116930

Run by

Mayo Clinic

People needed

18

Starts

2021-11-19

Expected to finish

2027-12-01

Last updated by the study team

2026-03-23

Who can join

Age: 18 and older, up to 54. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Post-dural puncture headache (PDPH) after documented dural puncture with Tuohy needle during placement of epidural analgesia for labor and no other explanation for headache (HA).
• Onset of HA within 72 hours of delivery.

You may not qualify if…

• Patient refusal.
• Visual analog scale (NRS) score < 4.
• History of migraine headaches.
• Asthma.
• Arrhythmia.
• Heart block.
• Myasthenia gravis.
• Inability to understand pain scores and other questionnaires.
• Inability to speak English.
• Contraindication to acetaminophen or NSAIDs.
• Temperature > 38.5 C.
• Prior EBP done for this HA.

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.